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Other names: ALL1, HRX, Htrx (human trithorax), 
TRX1 
Location: 11q23 





MLL (11q23) - Courtesy Mariano Rocchi, Resources for 
Molecular Cytogenetics.  
Description 
37 exons, spanning over 100 kb 
Transcription 
In a centromeric to telomeric direction; 13 and 15 kb; 






3969 amino acids; 431 KDa; contains from N-term to 
C-term 3 AT hooks homologous to high mobility group 
proteins HMGA1 and HMGA2, binding to the minor 
grove of DNA; 2 speckled nuclear localisation signals; 
2 repression domains RD1 and RD2: RD1 or CXXC: 
cystein methyl transferase, binds CpG rich DNA, has a 
transcriptional repression activity; RD2 recruits hi tone 
desacetylases HDAC1 and 2; 3 plant homeodomains 
(cystein rich zinc finger domains, with 
homodimerization properties), 1 bromodomain (may 
bind acetylated histones), and 1 plant homeodomain; 
these domains may be involved in protein-protein 
interaction; a FYRN and a FRYC domain; a 
transactivation domain which binds CBP; may 
acetylates H3 and H4 in the HOX area; a SET domain: 
methyltransferase; methyltates H3, including histones 
in the HOX area for allowing chromatin to be open to 
transcription. MLL is cleaved by taspase 1 into 2 
proteins before entering the nucleus: a p300/320 N-
term protein called MLL-N, and a p180 C-term protein, 
called MLL-C. The FYRN and a FRYC domains of 
native MLL associate MLL-N and MLL-C in a stable 
complex; they form a multiprotein complex with 
transcription factor TFIID. 
Expression 
Wide; especially in: brain, kidney, thyroid; express d 
in Taned B lymphocytes and myeloid cells. 
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 MLL partner genes - Rolf Marschalek Nov 2002. 
 
Localisation 
Nuclear, in punctate spots. 
Function 
Transcriptional regulatory factor; MLL may have yin-
yang functions though actions of MLL-N and MLL-C 
(e.g. desacetylation/acetylation); MLL-N acts as a 
transcriptional repressor; MLL can be associated with 
more than 30 proteins, including the core components 
of the SWI/SNF chromatin remodeling complex and 
the transcription complex TFIID. MLL binds 
promotors of HOX genes through acetylation and 
methylation of histones. MLL is a major regulator of 
hematopoesis and embryonic development, through 
regulation of HOX genes expression regulation 
(HOXA9 in particular). 
Homology 
Trithorax (Drosophila), ALR (human), MLL2 (human). 
Mutations 
Note: MLL is implicated in at least 10 % of acute 
leukaemias (AL) of various types: acute lymphoblastic 
leukemias (ALL), acute non lymphocytic leukemias 
(ANLL), biphenotypic ALs, treatment related 
leukemias, infant leukemias; the prognosis is poor. 
Implicated in 
t(4;11)(q21;q23)/acute leukaemias → 
MLL-AFF1 (AF4) 
Disease 
Typically CD19+ CD10-precursor B-ALL, 
biphenotypic AL, at times ANLL (M4/M5); common in 
infants may be congenital; treatment related leukaemi  
(secondary to epipodophyllotoxins). 
Prognosis 
Median survival < 1 year 
Cytogenetics 
Additional chromosome anomalies are found in 1/4 of 
cases, one of which is the i(7q). 
Hybrid/Mutated Gene 
5' MLL - 3' AF4; 12kb. 
Abnormal Protein 
240 kDa protein with about 1400 aminoacids from 
NH2 MLL and 850 from COOH AF4 (variable 
breakpoints); the reciprocal may or may not be 
expressed. 
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t(6;11)(q27;q23)/ANLL → MLL-MLLT4 
(AF6) 
Disease 




t(9;11)(p22;q23) /ANLL → MLL-MLLT3 
(AF9) 
Disease 
M5/M4 de novo and therapy related ANLL. 
Prognosis 
The prognosis may not be as poor as in other 11q23 
leukaemias in de novo cases; very poor prognosis in 
secondary ANLL cases. 
 
Cytogenetics 
May be overlooked; often as a sole anomaly. 
Hybrid/Mutated Gene 
Variable breakpoints on both genes. 
Abnormal Protein 
N-term - AT hook and DNA methyltransferase from 
MLL fused to the 192 C-term amino acids from AF9 
(as breakpoints are variable, this is only an example). 
t(10;11)(p12;q23)/ANLL → MLL-MLLT10 
(AF10) 
Disease 
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t(11;19)(q23;p13.1)/ANLL → MLL-ELL 
Disease 




Detected with R banding. 
Hybrid/Mutated Gene 
5' MLL - 3' ELL. 
Abnormal Protein 
AT hook and DNA methyltransferase from MLL fused 
to most of ELL. 
Oncogenesis 
Potential transcription factor. 
t(11;19)(q23;p13.3)/acute leukaemias → 
MLL-MLLT1 (ENL) 
Disease 
ALL (CD19+), biphenotypic AL, ANLL (M4/M5); 
mainly congenital; treatment-related leukaemia. 
Prognosis 
Very poor, except in rare T-cell cases. 
Cytogenetics 
Detected with G banding. 
Hybrid/Mutated Gene 
5' MLL - 3' ENL. 
Abnormal Protein 
AT hook and DNA methyltransferase from MLL fused 
to, most often, the nearly entire ENL. 
Other entities 
•  t(X;11)(q13;q23)/ANLL, T-ALL → MLL - AFX1 
•  t(X;11)(q22;q23)/ANLL → MLL- Septin2 
•  t(1;11)(p32;q23)/ALL → MLL- EB15 (AF1p) 
•  t(1;11)(q21;q23)/ANLL → MLL- MLLT11 (AF1q) 
•  t(2;11)(q11;q23)/ALL → MLL- AFF3 (LAF4) 
•  t(3;11)(p21;q23)/t-ANLL, ALL→ MLL- NCKIPSD 
(AF3p21) 
•  t(3;11)(q21;q23)/ALL → MLL- EEFSEC (SELB) 












•  t(3;11)(q28;q23)/ANLL → MLL - LPP 
•  t(4;11)(p12;q23) → MLL - AF4p12 
•  t(4;11)(q12;q23) → MLL - MIFL 
•  t(4;11)(q21;q23)/atypical CML → MLL - SEPT11 
•  t(4;11)(q35;q23)→ MLL - ArgBP2 
• t(5;11)(q31;q23)/ANLL, ALL → MLL - ARHGAP26 
(GRAF) 
• ins(5;11)(q31;q13q23)/ALL → MLL - AFF4 
(AF5q31) 
•  t(6;11)(q12;q23)/ANLL → MLL - SMAP1 
• t(6;11)(q21;q23)/ANLL → MLL - FOXO3A 
(AF6q21) 
• t(9;11)(q34;q23)/ANLL → MLL - DAB2IP 
(AF9q34) 
•  t(10;11)(p11;q23)/ANLL → MLL - ABI1 
•  t(10;11)(q21;q23)/ANLL → MLL - CXXC6 (TET1) 
•  t(11;11)(q21;q23)/ANLL → MLL - PICALM 
•  trisomy 11/ANLL → MLL tandem duplication 
•  t(11;11)(q23;q23)/ANLL → MLL - CBL 
• t(11;11)(q23;q23)/ANLL → MLL - ARHGEF12 
(LARG) 
•  t(11;11)(q23;q24)/ANLL → MLL - TIRAP 
•  t(11;12)(q23;q13)/ANLL → MLL - CIP29 
•  t(11;14)(q23;q24)/ANLL, AUL → MLL - GPHN 
• t(11;15)(q23;q14)/ANLL, ALL → MLL - CASC5 
(AF15q14) 
•  t(11;15)(q23;q14) → MLL - MPFYVE 
•  t(11;15)(q23;q15) → MLL - AF15 
• t(11;16)(q23;p13)/MDS, ANLL, t-ANLL, ALL → 
MLL - CREBBP (CBP) 
•  t(11;17)(q23;p13)/t-ANLL → MLL - GAS7 
•  t(11;17)(q23;q21)/ANLL → MLL - ACACA 
•  t(11;17)(q23;q21)/ANLL → MLL - LASP1 
• t(11;17)(q23;q21)/ANLL → MLL - MLLT6 (AF17) 
•  t(11;17)(q23;q21)/ANLL → MLL - RARa 
•  t(11;17)(q23;q25)/MDS, ANLL → MLL - SEPT9 
(MSF1, AF17q25) 
• t(11;19)(q23;p13)/ANLL → MLL - SH3GLI1 (EEN) 
•  t(11;19)(q23;p13)/ANLL → MLL - MYO1F 
•  t(11;20)(q23;q11)/ALL → MLL - MAPRE1 (EB1) 
• t(11;22)(q23;q11.2)/ANLL → MLL - SEPT5 
(hCDCRel) 
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Breakpoints 
Note: spanning a 8 kb genomic region; between exons 5 to 11; highly variable on the partner, ranging from close to the 
NH2-term in MLLT1 (ENL), to near the COOH-term in MLLT3 (AF9). 
 
To be noted 
Note: the card on 11q23 rearrangements, gives an 
overview on diseases implicating MLL, as well as 
11q23 rearrangements in therapy related leukemias. 
See also 11q23 rearrangements in childhood acute 
lymphoblastic leukemia: Clinical aspects and 
congenital leukemias. 
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